New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:17 EDTAMGN, ESRXAmgen to see minimal impact from coverage changes, says RBC Capital
RBC Capital believes that Express Scripts' (ESRX) decision to refrain from covering Epo and Aranesp in 2015 will have minimal impact on Amgen (AMGN). The firm thinks Express Scripts' decision may have caused Amgen's stock to be weak versus its peers on Friday. The firm keeps an Outperform rating on Amgen.
News For AMGN;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 2, 2015
07:17 EDTAMGNCelimmune announces Anti-IL-15 antibody licensing, option agreements with Amgen
Subscribe for More Information
March 1, 2015
19:08 EDTAMGNAmgen ENDEAVOR study demonstrates superiority of Kyprolis over Velcade
Amgen and its subsidiary Onyx Pharmaceuticals announced the results from a planned interim analysis showing that the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis, carfilzomib, for Injection in combination with low-dose dexamethasone versus Velcade, bortezomib and low-dose dexamethasone met the primary endpoint of progression-free survival, PFS. Patients with relapsed multiple myeloma treated with Kyprolis lived twice as long without their disease worsening, demonstrating statistically and clinically significant superiority over Velcade. The Kyprolis combination demonstrated superiority over the Velcade combination for secondary objectives of higher overall response rate and lower neuropathy events. Overall survival data are not yet mature and continue to be monitored. Treatment discontinuation due to adverse events and on-study deaths were comparable between the two arms. The rates of cardiac failure and renal failure for Kyprolis were comparable to those observed in the Phase 3 ASPIRE study. In ENDEAVOR, the rates for cardiac and renal failure were higher in the Kyprolis arm versus the Velcade arm. There was an increase in the incidence of hypertension and dyspnea in the Kyprolis arm compared to Velcade and that observed in the ASPIRE study.
February 27, 2015
09:03 EDTAMGNAmgen receives positive CHMP opinion for use of Vectibix
Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion to extend the marketing authorization for Vectibix to include combination with FOLFIRI as first-line treatment in adult patients with wild-type RAS metastatic colorectal cancer. About half of the patients with mCRC have wild-type RAS tumors.The new indication is based upon the 20060314 study, which evaluated Vectibix plus FOLFIRI in the first-line setting. Vectibix is already approved in the European Union for the treatment of adult patients with wild-type RAS mCRC.
07:37 EDTAMGNAmgen removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:26 EDTAMGNFDA PDUFA Date for Amgen's Ivabradine is February 27, 2015
February 26, 2015
16:35 EDTAMGNAmgen reports EMA acceptance of Kyprolis
Amgen and its subsidiary Onyx Pharmaceuticals announced that the European Medicines Agency, or EMA, has accepted the Marketing Authorization Application, or MAA, of Kyprolis for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA has been granted accelerated assessment by the EMA. Kyprolis is a proteasome inhibitor, one of the classes of drugs used to treat multiple myeloma, an incurable blood cancer affecting approximately 89,000 people in Europe. Nearly all patients with the disease experience periods of remission, followed by relapses and eventually their disease becomes resistant to treatment. The MAA includes data from the Phase 3 ASPIRE trial as well as other relevant data.
07:36 EDTESRXExpress Scripts price target raised to $90 from $85 at Leerink
Subscribe for More Information
February 25, 2015
16:50 EDTAMGNAmgen reports positive results from head-To-head Phase 3 study
Subscribe for More Information
10:11 EDTESRXExpress Scripts says willing to do 'tranformational' deal
Subscribe for More Information
February 24, 2015
13:23 EDTESRXLeerink healthcare technology analyst holds analyst/industry conference call
Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.
February 23, 2015
18:02 EDTESRXOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTESRXExpress Scripts sees Q1 EPS $1.07-$1.11, consensus $1.16
Subscribe for More Information
16:03 EDTESRXExpress Scripts sees FY15 EPS $5.35-$5.49, consensus $5.44
Subscribe for More Information
16:02 EDTESRXExpress Scripts reports Q4 EPS 1.39, consensus $1.38
Subscribe for More Information
15:23 EDTESRXNotable companies reporting after market close
Subscribe for More Information
06:28 EDTESRXExpress Scripts weekly volatility elevated into Q4 and outlook
Subscribe for More Information
February 18, 2015
05:36 EDTESRXExpress Scripts to host investor meeting
Investor meeting to be held in St. Louis on February 25 at 8:30 am. Webcast Link
February 17, 2015
18:17 EDTAMGNJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
17:29 EDTESRXBerkshire Hathaway gives quarterly update on stakes, exits Exxon Mobil
Subscribe for More Information
10:01 EDTAMGNCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use